Co-Authors
This is a "connection" page, showing publications co-authored by MICHAEL JAMES OVERMAN and ANDREW FUTREAL.
Connection Strength
0.413
-
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022 08; 10(8).
Score: 0.211
-
Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma. Cancer Res Commun. 2024 05 29; 4(5):1363-1368.
Score: 0.060
-
An analysis of research biopsy core variability from over 5000 prospectively collected core samples. NPJ Precis Oncol. 2021 Oct 27; 5(1):94.
Score: 0.050
-
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 11; 11(11):2738-2747.
Score: 0.049
-
Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clin Cancer Res. 2020 03 15; 26(6):1385-1394.
Score: 0.044